Keyphrases
Colorectal Cancer
85%
Neoadjuvant Chemoradiotherapy (nCRT)
56%
Tumor
47%
Radiotherapy
42%
5-fluorouracil (5-FU)
41%
Esophageal Cancer
40%
Neoadjuvant Therapy
39%
Cisplatin
37%
Advanced Esophageal Cancer
32%
Israel
32%
Positron Emission Tomography-computed Tomography (PET-CT)
32%
Pathological Complete Response
31%
Gastric Cancer
31%
Overall Survival
27%
Concurrent Chemoradiotherapy
26%
Leucovorin
24%
18F-FDG PET-CT
24%
Tumor Regression Grade
21%
Locally Advanced Rectal Cancer
21%
Treatment Options
21%
Disease-free Survival
20%
Preoperative Chemoradiation
20%
Chemoradiation
19%
Adenocarcinoma
19%
Partial Response
18%
Chemoradiotherapy
18%
Esophageal Adenocarcinoma
17%
Locally Advanced
17%
Young Patients
17%
Capecitabine
17%
Pathological Response
17%
Advanced Gastric Cancer
16%
Cetuximab
16%
Bevacizumab
16%
Biochemical Failure
16%
Clinical Entities
16%
Early Prediction
16%
Phase II Study
16%
Brain Metastases
16%
Three-dimensional Conformal Radiotherapy
16%
5-year Survival
15%
Radiation Therapy
14%
Neoadjuvant
14%
Cancer Patients
14%
Rectal Tumor
14%
Diarrhea
13%
Prognostic Factors
13%
Histological Response
13%
Docetaxel
12%
MicroRNA
12%
Medicine and Dentistry
Chemoradiotherapy
100%
Neoplasm
80%
Rectum Cancer
77%
Radiation Therapy
49%
Esophageal Cancer
42%
Positron Emission Tomography-Computed Tomography
40%
Neoadjuvant Therapy
37%
Colorectal Cancer
36%
Adenocarcinoma
31%
Retrospective Study
27%
Overall Survival
26%
Malignant Neoplasm
25%
Colon Cancer
24%
Stomach Cancer
24%
Prognostic Factor
19%
Disease
18%
Tumor Regression
18%
Breast Cancer
17%
Disease Free Survival
17%
Esophageal Adenocarcinoma
17%
Recurrent Disease
16%
Fluorine-18
16%
Fluorodeoxyglucose F 18
16%
Brain Metastasis
16%
Biochemical Recurrence
16%
Folinic Acid
16%
microRNA
16%
Conformal Radiotherapy
16%
Surgery
12%
Gastroesophageal Junction
12%
Neoadjuvant Chemotherapy
12%
Sphincter
12%
Rectum Tumor
11%
Primary Tumor
11%
Computer Assisted Tomography
11%
Cancer Treatment
11%
Fluorouracil
11%
Hazard Ratio
10%
Squamous Cell Carcinoma
10%
Pelvic Radiotherapy
10%
Prostate Cancer
9%
Capecitabine
9%
Signet Ring Cell
9%
Lymph Node
9%
Positron Emission Tomography
9%
Metastatic Carcinoma
9%
Survival Rate
8%
Family History
8%
Biopsy
8%
Systematic Review
8%
Pharmacology, Toxicology and Pharmaceutical Science
Chemoradiation Therapy
99%
Stomach Cancer
62%
Neoplasm
55%
Rectum Cancer
48%
Cisplatin
39%
Fluorouracil
38%
Chemotherapy
33%
Esophagus Cancer
29%
Disease
26%
Overall Survival
26%
Adenocarcinoma
22%
Malignant Neoplasm
19%
Colorectal Cancer
18%
Capecitabine
17%
Recurrent Disease
17%
Cetuximab
16%
microRNA
16%
Colon Cancer
16%
Docetaxel
16%
Bevacizumab
16%
Biochemical Recurrence
16%
Folinic Acid
16%
Brain Metastasis
16%
Retrospective Study
13%
Survival Rate
12%
Disease Free Survival
12%
Primary Tumor
11%
Prostate Cancer
10%
Tolerability
10%
Breast Cancer
9%
Progression Free Survival
8%
Fluorine 18
8%
Prospective Cohort Study
8%
microRNA 29a
8%
Fluorodeoxyglucose F 18
8%
Gemcitabine
8%
Esophageal Squamous Cell Carcinoma
8%
Stomach Carcinoma
8%
Pancreas Cancer
8%
Bone Metastasis
8%
Liver Cell Carcinoma
8%
Minimal Residual Disease
8%
Long Term Survival
8%
Diarrhea
7%
Metastasis
6%
Tumor Regression
6%
Tree
5%